Team spirit is our key to success

The Versameb team consists of a number of senior experts in drug development and business building, complemented by a strong advisory team with research, clinical, technical and commercialization expertise.

KLAAS ZUIDEVELD
CHIEF EXECUTIVE OFFICER & MEMBER OF THE BOARD

Dr. Klaas Zuideveld brings over 20 years of drug development and life science industry experience to Versameb at a pivotal stage in the Company’s development as two of its lead assets transition from early discovery into clinical development. Klaas joined Versameb as Chief Development Officer in May 2020. Prior to this, Klaas has held leadership positions at Roche where amongst other things he has led the clinical development of Avastin™ (bevacizumab), and at Caris Life Sciences where he was responsible for the company’s first companion diagnostic partnership in oncology. He has further worked for and advised Mosaic Biomedicals (acquired by Northern Biologic), T3 Pharma, Envision Sciences, Therachon (acquired by Pfizer for $340 million upfront plus $470 million contingent payments) and Nucleai.

FRIEDRICH METZGER
CHIEF SCIENTIFIC OFFICER, CO-FOUNDER & MEMBER OF THE BOARD

Prof. Dr. Friedrich Metzger, a scientist and co-founder of Versameb, has an over 18 years’ experience in R&D both in pharma and biotech. Previously, Friedrich was Head of Discovery, Rare Diseases at Roche, Basel, where he was responsible for a portfolio of highly innovative development programs. He led preclinical activities for Evrysdi™ (risdiplam), a groundbreaking oral therapy for spinal muscular atrophy which was very recently approved. Friedrich is also Professor in Neurobiology at the University of Freiburg, Germany, and holds a PhD degree in pharmacology from the University of Tübingen, Germany.

Friedrich Metzger Versameb

ISABEL FERREIRA
CHIEF BUSINESS OFFICER

Dr. Isabel Ferreira joined Versameb in August 2019 as Chief Business Officer. Previously, she served Roche Partnering since 2015 as Director Global Business Development. In this role, she had broad responsibility across Pharma Business Development including strategy, search, evaluation, senior stakeholder management, leading cross-functional due diligence and negotiation teams to deal closure. Before joining Roche, Isabel served as Senior Director Business Development at Prosensa. During this time, she was instrumental in establishing transformative licensing transactions, supporting non-dilutive and private financing events, project management of Prosensa’s IPO launch at NASDAQ and supporting Prosensa’s acquisition by BioMarin. Earlier in her career, Isabel has been exposed to different aspects of the biopharmaceutical industry at Janssen-Cilag (Portugal), OctoPlus (The Netherlands) and Theravance (USA) in commercial, drug development and scientific roles. Isabel holds a Ph.D. in Biochemistry from the University of Groningen (The Netherlands) and an MBA from the Rotterdam School of Management (RSM), Erasmus University (The Netherlands).

URS BREITENSTEIN
CHIEF FINANCE OFFICER

Dr. Urs Breitenstein, an economist and co-founder of Versameb, is senior finance specialist with comprehensive experience from various assignments in companies in the life sciences sector at different maturity stages. As a partner of Hoffmann & Co AG, a Swiss M&A, valuation and CFO services company, he is acting as interim or part time CFO, business advisor or as a board member for companies and investors. In his previous roles, he served as a partner and team leader at international professional service firms (PwC, Deloitte) providing valuation, corporate finance and M&A services. He supported many large and mid-sized transactions in Switzerland and internationally both in life sciences as well as manufacturing and services. He is a graduate of the postgraduate study center of the Swiss National Bank at Gerzensee and holds a doctorate in economics from the University of Basel.

Urs Breitenstein Versameb
Reinhard Ambros

REINHARD AMBROS
CHAIRMAN OF THE BOARD

In his career Dr. Reinhard Ambros has gained broad experience in international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. He serves on the board of public and private bio-technology companies in Europe and the US. He also serves as advisor to German and Swiss Government Biotechnology Funds. Over the past 12 years Dr. Ambros built the Novartis Venture Fund to a leading corporate biotechnology fund.

EUGENE TIERNEY
MEMBER OF THE BOARD

Eugene Tierney is an experienced business strategist and has held senior positions across the whole pharma value chain. He spent several years as head of global pharma business strategy with Roche, before becoming Therapeutic Area Head for Anti-infectives & Transplantation. He was later appointed Head of Neuroscience, with accountability for all aspects of discovery and early development, as well as commercialisation. He currently works as a consultant to pharma and biotech companies and is a non-executive director on the boards of a number of privately owned biotech companies.

Eugene Tierney versameb team

BETTINA ERNST
MEMBER OF THE BOARD

Dr. Bettina Ernst has been investing in healthcare companies for the past 6 years. She also serves on the board of several early-stage biotech companies in Switzerland, on the board of the Swiss Biotech Association, and as a member of the advisory board of the Swiss Entrepreneur Fund and of the Innovation Council of Innosuisse. Bettina is a co-founder of two biotech companies. Prior to her investment and entrepreneurial activities, she worked for 10 years in fundamental immunology in the US (Scripps Research Institute, San Diego, CA) and in Europe. Bettina holds a PhD in immunology and an undergraduate degree in natural science from the Federal Institute of Technology (ETH) in Zurich. Bettina resides in Switzerland.